NewslettersHematopoiesis NewsUncategorizedA Phase II Study of Sorafenib Combined with Conventional Therapies in Refractory Central Nervous System LeukemiaBy Justin.choi - March 22, 202209To explore the efficacy of sorafenib combined with conventional therapies for refractory central nervous system leukemia, a Phase II study was conducted.[Cancer] 6445212 BBBBBBBB items 1 apa 0 default asc 1 173149 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Abstract